International Journal of Multidisciplinary Research and Growth Evaluation.

Improving Access to Essential Medications in Rural and Low-Income U.S. Communities: Supply Chain Innovations for Health Equity

Kolade Seun Adeyemo [1*], Akachukwu Obianuju Mbata [2], Obe Destiny Balogun [3]
[1] May & Baker Nigeria PLC, Ikeja, Lagos, Nigeria
[2] Kaybat Pharmacy and Stores, Benin, Nigeria
[3] Independent Researcher, Lima Ohio, USA

* Corresponding Author: **Kolade Seun Adeyemo**

Article Info

Article Info
ISSN (online): 2582-7138
Volume: 04
Issue: 01
March-April 2023
Received: 12-01-2023
Accepted: 17-02-2023
Page No: 1181-1187

Abstract
Access to essential medications in rural and low-income U.S. communities remains a critical challenge, exacerbated by geographic isolation, economic constraints, and inefficient supply chains. These barriers often result in limited medication availability, delayed treatments, and higher health risks for vulnerable populations. This paper explores the role of supply chain innovations in addressing these disparities, focusing on decentralized distribution models, technology-driven solutions, and public-private partnerships. It examines the potential of mobile pharmacies, micro-fulfillment centers, AI-driven demand forecasting, and blockchain technology to improve medication delivery efficiency and accessibility. Furthermore, the paper discusses the regulatory and policy frameworks necessary to support these innovations, proposing recommendations for federal and state governments to incentivize new models and expand coverage for underserved communities. The paper concludes with a call for future research on scalable models and long-term sustainability, ensuring that these innovations contribute to health equity in the future.

DOI: https://doi.org/10.54660/.IJMRGE.2023.4.1.1181-1187

Keywords: Medication Access, Supply Chain Innovation, Health Equity, Rural Healthcare, Technology in Healthcare, Public-Private Partnerships

1. Introduction
The issue of access to essential medications remains a significant challenge in the healthcare systems of many nations, and in the U.S., the problem is particularly acute for rural and low-income communities. These communities face distinct barriers that hinder their ability to acquire necessary medications, ultimately contributing to poorer health outcomes and exacerbating existing health disparities (Wirtz, Kaplan, Kwan, & Laing, 2016) [34]. This paper's central focus is exploring how innovative supply chain solutions can help mitigate these barriers and improve access to essential medicines for marginalized populations. By addressing the various structural, economic, and logistical challenges that hinder access to medications, supply chain innovations hold the potential to create more equitable healthcare delivery systems (Balogun *et al*., 2023) [6].
Access disparities in medications refer to the unequal distribution of pharmaceutical resources, with certain populations facing higher costs, longer wait times, and limited availability of necessary drugs (Baeten, Spasova, Vanhercke, & Coster, 2018) [5]. In the U.S., this issue is particularly prominent in rural and low-income communities where pharmacy deserts, inadequate infrastructure, and high medication prices are common. These communities experience limited access to local healthcare facilities, and even fewer options for obtaining essential medications. For individuals living in these regions, traveling long distances to the nearest pharmacy or healthcare provider can become a significant financial burden.
Rural areas often face the compounded issue of geographic isolation (Satcher, 2022) [30]. These communities may lack physical proximity to medical services, including pharmacies, and may not have access to specialists or even basic primary care. This not

only affects the timely acquisition of medication but also creates an environment where individuals are unable to easily discuss their prescriptions with healthcare professionals. In rural areas, some individuals might not have the means or transportation to travel for prescriptions, making it difficult to maintain a consistent and continuous supply of necessary medications. For low-income populations, these issues are often exacerbated by financial constraints that limit the affordability of medications and healthcare in general (Chow *et al*., 2018) [9].

Moreover, the cost of medications is a major barrier for many individuals in rural and low-income communities. High out-of-pocket costs due to limited insurance coverage or lack of access to government programs can prevent people from purchasing necessary medications. Individuals may sometimes be forced to make difficult decisions about prioritizing medication or other basic needs, such as food or housing. Medication non-adherence is often a result of these cost-related challenges and leads to worsened health conditions, increased hospitalizations, and long-term healthcare burdens that ultimately affect both the individuals and the healthcare system at large (Majebi, Drakeford, Adelodun, & Chinyere, 2023) [24].

In response to these challenges, supply chain innovations have emerged as a key solution for enhancing the accessibility and affordability of essential medications. Advances in technology, distribution methods, and collaboration across sectors can help bridge the current gaps in the healthcare supply chain (Dutta, Choi, Somani, & Butala, 2020) [12]. By leveraging these innovations, it is possible to overcome geographic, economic, and logistical barriers, enabling more equitable access to essential drugs. Decentralized supply chains, for example, could enable medications to be delivered directly to individuals in remote areas, reducing reliance on physical pharmacies and ensuring that patients receive their prescriptions promptly. Additionally, digital platforms and telemedicine services can connect patients with healthcare professionals, allowing for virtual consultations and prescriptions, further enhancing medication access (Haleem, Javaid, Singh, & Suman, 2021) [14].

The research objective of this paper is to explore how supply chain innovations can effectively address the existing disparities in access to medications in rural and low-income communities. This paper will examine various innovations in pharmaceutical distribution, including mobile pharmacies, micro-fulfillment centers, and telepharmacy services. Furthermore, it will explore the role of public-private partnerships, policy changes, and technological advances such as artificial intelligence and blockchain in ensuring the equitable distribution of essential drugs. The goal is to identify and evaluate potential solutions that can be scaled up to improve access, reduce costs, and ultimately contribute to health equity across the U.S.

This paper argues that improving access to essential medications through innovative supply chain solutions is not only a matter of logistical efficiency but also a critical step in addressing broader health disparities and achieving health equity. By understanding the challenges faced by rural and low-income communities and assessing potential solutions, the paper seeks to contribute to ongoing discussions and initiatives to improve medication access and healthcare outcomes for all Americans, regardless of their geographic or economic status.

2. Key barriers to medication access

2.1 Geographic Disparities

One of the most significant barriers to medication access in rural and low-income communities is the geographic isolation of these populations. In many rural areas, there is a limited presence of pharmacies, directly impacting residents' ability to access essential medications. For instance, in rural regions, individuals may need to travel significant distances to reach the nearest pharmacy, and in some cases, there may be no pharmacy within a reasonable range. Other infrastructure challenges, including inadequate roads, insufficient public transportation systems, and low availability of healthcare facilities compound this geographic limitation. The result is that individuals in these areas experience a delay in receiving prescriptions, which can lead to a delay in treatment and worsening health conditions (Lazar & Davenport, 2018) [21].

The transportation issues faced by residents in rural areas further exacerbate this problem. Many individuals lack access to a personal vehicle, and public transportation options may be minimal or nonexistent. This creates a transportation barrier, making it challenging for individuals to pick up medications from distant pharmacies, especially those with chronic conditions requiring frequent refills. For older adults, individuals with disabilities, or those who cannot afford transportation services, the difficulty of traveling long distances can significantly impact their ability to access medication consistently. The inability to access medications promptly can lead to medication non-adherence, which can worsen health outcomes, increase the need for emergency services, and ultimately escalate healthcare costs for both individuals and the healthcare system.

2.2 Economic Constraints

Economic constraints are another major barrier to medication access. Even if medications are available in nearby pharmacies, high prices can prevent individuals in rural and low-income communities from purchasing essential drugs. The cost of medications in the U.S. has risen dramatically in recent decades, and this trend disproportionately affects individuals with lower incomes who are already struggling with other financial challenges (Wirtz *et al*., 2016) [34]. For those without insurance or with inadequate insurance coverage, out-of-pocket costs can be prohibitive, leading some individuals to forgo medications altogether or to only take medications intermittently. Medication non-adherence due to cost is a significant issue, with studies showing that individuals who cannot afford their prescriptions are more likely to experience adverse health outcomes, such as increased hospitalizations or emergency department visits (Bors, Christie, Gervais, & Wright Clayton, 2015) [8].

In addition to high medication prices, the lack of insurance coverage or inadequate insurance plans is another factor that exacerbates medication access issues. Medicaid, the government program designed to provide health coverage for low-income individuals, may not cover the full range of essential medications, and insurance plans in low-income communities may have limited formularies that exclude necessary treatments (Kesselheim, Avorn, & Sarpatwari, 2016) [16]. High co-pays and deductibles can make medications unaffordable even for individuals with insurance. Furthermore, many pharmaceutical companies engage in pricing inefficiencies, such as price gouging and lack of transparency in pricing, which makes it difficult for

consumers to understand the actual cost of medications and for health systems to effectively manage drug expenses (Luiza *et al*., 2015) [22].

The economic burden of accessing essential medications is particularly acute in rural areas where poverty rates are often higher, and healthcare infrastructure is weaker. In these areas, individuals are more likely to lack access to employer-sponsored health insurance, leaving them reliant on public programs that may not fully meet their needs. This economic disparity leads to a situation where individuals are forced to choose between purchasing medications and meeting other basic needs, such as food and housing, further contributing to poor health outcomes (Alli & Dada, 2023a; Babarinde, Ayo-Farai, Maduka, Okongwu, & Sodamade, 2023) [2, 4, 6].

2.3 Supply chain inefficiencies

Supply chain inefficiencies in the pharmaceutical sector also play a critical role in hindering access to medications. The U.S. pharmaceutical supply chain is a complex network involving manufacturers, wholesalers, distributors, and pharmacies, all of which must work together to ensure that medications are available where and when needed. However, this system is often inefficient, leading to significant delays in medication availability, particularly in underserved regions (Singh, Kumar, & Kumar, 2016) [31]. Drug shortages are frequent, with some essential medications becoming unavailable for extended periods. This can happen for various reasons, including manufacturing disruptions, raw material shortages, and regulatory issues. When these shortages occur, pharmacies in rural and low-income areas may struggle to procure critical medications, leaving patients without necessary treatments (Moosivand, Ghatari, & Rasekh, 2019) [25].

Another significant issue is distribution bottlenecks. Medications are often distributed through a centralized system that is designed for urban and suburban markets, where demand is high. This system may not be well-suited to rural areas, where demand is lower but still requires timely delivery. Longer shipping routes, limited transportation infrastructure, and low-volume orders may delay medication delivery in rural areas. Additionally, many small, independent pharmacies in rural areas lack the purchasing power or infrastructure to manage complex supply chains, leading to fragmented logistics. These logistical inefficiencies further exacerbate the difficulties faced by rural and low-income communities in obtaining medications (Magnusson, 2020) [23].

2.4 Regulatory and policy challenges

Finally, regulatory and policy challenges are significant barriers to medication access in rural and low-income communities. One of the primary challenges is the limitations of Medicaid, the government program that provides health coverage to low-income individuals. Medicaid programs vary by state, and many states have stringent eligibility requirements, leaving individuals just above the poverty line without coverage. Furthermore, Medicaid often imposes restrictions on the types of medications covered, and these restrictions can result in patients being unable to obtain essential drugs. Additionally, Medicaid reimbursement rates for pharmacies, particularly in rural areas, are often low, making it financially unviable for some pharmacies to provide medications at affordable rates. As a result, some pharmacies may close, leaving communities without access to essential medications (Nuffer, Trujillo, & Griend, 2019) [26].

There are also regulatory hurdles related to the supply chain itself. The complex system of pharmaceutical regulations at the state and federal levels creates barriers to efficient medication distribution. For example, regulatory restrictions on the interstate distribution of drugs can delay the movement of medications to underserved areas. Similarly, policies related to controlled substance distribution can limit certain medications' availability in rural areas. These regulatory constraints can disrupt the flow of medications, making it difficult for individuals in rural and low-income communities to obtain the drugs they need.

In conclusion, geographic disparities, economic constraints, supply chain inefficiencies, and regulatory challenges all play a role in restricting access to essential medications in rural and low-income U.S. communities. These barriers are interconnected and require comprehensive solutions that address the root causes of medication access issues.

3. Supply chain innovations for health equity

3.1 Decentralized distribution models

One of the most promising supply chain innovations for improving access to essential medications is the implementation of decentralized distribution models. These models aim to move away from traditional centralized distribution systems that often struggle to serve rural and low-income communities. Instead, they leverage local solutions that ensure medications are delivered directly to needy patients, regardless of their location.

Mobile pharmacies are a key example of this decentralized approach. These fully-equipped pharmacies operate out of specially designed vehicles, allowing pharmacists to travel to underserved communities to provide medications, consultations, and health services. By bringing pharmacy services directly to rural areas, mobile pharmacies eliminate the need for individuals to travel long distances to access medications, which is especially important in areas with poor transportation options. Additionally, mobile pharmacies can be used to deliver vaccinations, health screenings, and other essential services, making them a comprehensive healthcare resource for isolated communities.

Another promising innovation is the development of micro-fulfillment centers, which are small, local warehouses designed to efficiently store and distribute medications. These centers are strategically placed in underserved areas and are equipped with automated systems that can quickly process orders and ship medications directly to patients or local pharmacies. Micro-fulfillment centers are often more cost-effective and flexible than larger distribution hubs and can be set up to meet the specific needs of a given region. By enabling faster delivery and reducing costs associated with transportation and storage, micro-fulfillment centers make it easier for individuals in rural areas to access essential drugs in a timely manner (Alli & Dada, 2023b) [3].

3.2 Technology-driven solutions

Technology is playing an increasingly crucial role in improving the efficiency and transparency of the medication supply chain. AI-driven demand forecasting, blockchain for supply chain transparency, and telepharmacy are innovations that help streamline pharmaceutical distribution and ensure that medications are available when and where they are needed. AI-driven demand forecasting uses machine learning

algorithms to predict medication needs based on seasonal trends, historical data, and patient health patterns (Talla, 2022) [32]. This technology can help pharmacies and suppliers anticipate demand more accurately, reducing the likelihood of shortages or overstock situations. In rural and low-income communities, this capability ensures that the right medications are available at the right time, minimizing disruptions in care. By optimizing inventory management, AI can help ensure that medications are available and delivered cost-effectively (Adekola, Kassem, & Mbata, 2022) [1].

Blockchain technology is another important innovation for improving the transparency of the pharmaceutical supply chain. By providing an immutable digital record of every transaction, blockchain allows all stakeholders—from manufacturers to distributors to pharmacies—to track the movement of medications in real-time. This creates greater accountability within the system and can help identify where inefficiencies or bottlenecks are occurring. Blockchain also improves the safety of the medication supply chain by reducing the risk of counterfeit drugs entering the market, which is a particularly critical concern in rural and low-income areas where patients may be more vulnerable to fraud (Saeed, Kohler, Cuomo, & Mackey, 2022) [29].

Telepharmacy is a technology-driven solution that enables pharmacists to provide remote consultation services, medication counseling, and prescription fulfillment through virtual platforms. This is particularly beneficial for individuals in rural areas with limited access to a physical pharmacy. Telepharmacy eliminates the need for patients to travel to a pharmacy in person, enabling them to receive guidance on their prescriptions and have their medications delivered to their homes or local facilities. This model also allows pharmacists to expand their reach, providing expertise to a broader patient population while reducing healthcare costs associated with in-person visits (Edoh, Ukpabi, & Igoli, 2021) [13].

3.3 Public-private partnerships

Public-private partnerships (PPPs) are essential in addressing the complex issue of medication access in underserved communities. These collaborations bring together government agencies, nonprofit organizations, and private-sector entities to combine their expertise, resources, and capabilities to create effective solutions. Each sector plays a unique role, with the government providing regulatory oversight and funding, nonprofits offering community-based insights and support, and private companies contributing logistical expertise and innovation.

For example, in some rural areas, pharmacy deserts can be alleviated through partnerships between government agencies and private pharmaceutical companies to fund the construction of mobile pharmacies or the establishment of new pharmacy sites in underserved regions. Nonprofits can assist in outreach efforts, ensuring that marginalized communities know the services available to them and helping connect patients with resources. Additionally, government programs like Medicaid and Medicare can provide the financial backing necessary to subsidize the costs of medications, making them more affordable for low-income individuals (Touger & Wood, 2019) [33].

These partnerships are also important for scaling up successful initiatives. What starts as a small, localized effort can be expanded to reach broader geographic areas and serve more individuals through the collaboration of multiple stakeholders. Furthermore, by pooling resources and sharing knowledge, public-private partnerships can more effectively navigate the complexities of healthcare regulation and pharmaceutical distribution, creating a cohesive and sustainable supply chain model.

3.4 Policy and financial innovations

Policy and financial innovations are critical in making medications more affordable and accessible to low-income and rural communities. Subsidized distribution models and the expansion of the 340B Drug Pricing Program are two significant policy innovations that can improve medication access for vulnerable populations (Conti, Nikpay, & Buntin, 2019) [10]. Subsidized distribution models aim to lower the cost of medications for individuals in rural and low-income areas. Under these models, pharmaceutical companies, distributors, and health systems may agree to provide medications at discounted rates or with reduced delivery fees to underserved populations. This helps offset the financial burden many individuals in these communities face when trying to access essential medications. Additionally, pharmacy benefit managers (PBMs) can negotiate better medication prices, ensuring that low-income individuals receive the same prices for drugs as their wealthier counterparts (Knox, Wang, Feldman, Kesselheim, & Sarpatwari, 2023) [18].

The 340B Drug Pricing Program is another key financial innovation designed to improve access to medications. The program requires pharmaceutical manufacturers to sell medications at reduced prices to eligible healthcare organizations, including community health centers, hospitals, and clinics that serve low-income and uninsured patients. Expanding the 340B program allows more healthcare providers to purchase medications at a reduced cost, passing those savings on to patients. By expanding eligibility and increasing funding for the program, more individuals in rural and low-income communities can benefit from lower medication prices, improving overall health outcomes and reducing the financial strain on healthcare systems (Knox, Kesselheim, & Sarpatwari, 2022) [17].

4. Implementation challenges and considerations

4.1 Infrastructure and logistics

One of the major hurdles to implementing supply chain innovations in underserved areas is the infrastructure and logistics required to deliver medications efficiently and reliably. Traditional distribution models are typically built around centralized warehouses and large-scale distribution networks, which are often ill-suited for rural areas where infrastructure limitations such as poor road networks and limited transportation options exist (Olatunji, Isarinade, Emmanuel, Olatunji, & Aderinto, 2023) [27].

Scalability is a key issue. While decentralized distribution models such as mobile pharmacies and micro-fulfillment centers can be effective in small-scale, pilot projects, scaling these models to serve a wider population requires significant investment in infrastructure. In rural areas, the existing logistics networks may need to be completely revamped to ensure that medications can be delivered on time and in sufficient quantities. This includes ensuring that these new systems can accommodate fluctuations in demand, seasonal variations, and population growth.

Another critical component of logistics in rural and low-income areas is the last-mile delivery. Last-mile delivery

refers to the final leg of the transportation process, where medications are delivered from local fulfillment centers or mobile pharmacies to the patients' homes or local healthcare providers. This can be particularly difficult in rural areas due to the lack of reliable transportation networks, low population density, and sometimes difficult-to-navigate terrain. Innovative solutions, such as using drones, local courier services, or collaborating with existing community delivery networks, may help overcome these challenges. However, such solutions must be implemented cost-effectively to avoid driving up prices for consumers (Ding, 2018) [11].

4.2 Data and technology barriers

Technology plays a central role in the proposed supply chain innovations, but several data and technology barriers must be addressed to ensure the success of these systems. A significant issue is the digital divide, which refers to the gap in access to digital tools and internet services between urban and rural populations. In many rural and low-income areas, high-speed internet is either unavailable or unaffordable (Saberi, Kouhizadeh, Sarkis, & Shen, 2019) [28]. This creates a significant barrier to the use of AI-driven demand forecasting, telepharmacy, and other digital health services that rely on robust internet connections. Without access to these technologies, the benefits of digital innovations cannot be fully realized, and patients in underserved communities may continue to face barriers in accessing medications.

Moreover, even in areas where the internet is accessible, there are issues surrounding interoperability between different digital systems. In the context of medication distribution, interoperability refers to the ability of various systems—such as pharmacy management software, supply chain management platforms, electronic health records (EHRs), and payment systems—to communicate seamlessly with one another. Without interoperability, critical data such as inventory levels, patient prescriptions, and shipment tracking may not be effectively shared, resulting in delays, errors, or inefficiencies in the medication supply chain. Ensuring that these systems are interoperable and that data flows smoothly across platforms is essential to improving medication access in underserved communities (Kouhizadeh, Saberi, & Sarkis, 2021) [19].

4.3 Regulatory Compliance

The regulatory environment in which the pharmaceutical supply chain operates presents several challenges to the implementation of innovative models aimed at improving medication access. FDA regulations and state-specific laws govern the approval, distribution, and dispensing of medications. These regulations are crucial for ensuring the safety, quality, and efficacy of medications but can also create barriers to innovation and flexibility in distribution systems. For instance, mobile pharmacies or telepharmacy initiatives may face significant regulatory hurdles in different states due to varying laws about who can dispense medications remotely and under what conditions. These regulations often fail to keep pace with technological advancements, resulting in a patchwork of rules that can complicate efforts to implement innovations consistently across the country.

In addition to regulatory hurdles, pharmaceutical supply chain security remains a persistent concern. The rise of online pharmacies, mobile dispensaries, and other new distribution models brings with it the risk of counterfeit drugs entering the system. Counterfeiting is a particularly serious issue in rural and low-income areas, where patients may be more vulnerable to fraudulent activities. Ensuring that medications are securely tracked and monitored through every stage of the supply chain, from manufacturer to patient, is essential to maintaining patient safety and confidence in the new systems. Blockchain and other technologies can help with this, but regulatory frameworks need to be updated to accommodate these tools and ensure the integrity of the supply chain (Krasting, 2021) [20].

4.4 Sustainability and long-term viability

For supply chain innovations to succeed in the long term, they must be financially sustainable and adaptable to changing circumstances. While many of the proposed models, such as micro-fulfillment centers or mobile pharmacies, may be effective in the short term, they require significant upfront investment in infrastructure, technology, and personnel. In rural and low-income areas, where resources are already limited, securing funding for such projects can be a challenge. Without adequate financial backing, these initiatives risk becoming unsustainable due to a lack of demand or an inability to cover operational costs.

Workforce challenges are also a significant consideration. Many of the proposed innovations require a highly skilled workforce, including pharmacists, technicians, supply chain managers, and IT professionals. Recruiting and retaining qualified personnel in rural areas, where there may be fewer opportunities for career advancement and professional development, can be difficult. Moreover, the workforce must be adequately trained to handle the specific challenges associated with rural healthcare, such as cultural competency and understanding the unique health needs of underserved populations. Without a dedicated and skilled workforce, even the best-designed supply chain innovations will struggle to succeed (Bardhan, Byrd, & Boyd, 2022) [7].

Finally, financial sustainability is linked to the ability to scale these models without compromising the affordability of medications. The cost of new distribution systems and technologies must be carefully weighed against the potential benefits to ensure that patients do not face higher out-of-pocket costs as a result of innovations. Policymakers, government entities, and private-sector stakeholders must work together to find funding solutions that can support these models' long-term viability while maintaining affordability for the most vulnerable populations (Jönsson *et al*., 2019) [15].

5. Conclusion and recommendations

Supply chain innovations present a transformative opportunity to bridge the gaps in medication access for underserved communities, particularly in rural and low-income areas. The research highlights that key barriers such as geographic isolation, economic constraints, and supply chain inefficiencies can be addressed through decentralized distribution models, technology-driven solutions, and policy innovations. By leveraging mobile pharmacies, micro-fulfillment centers, and AI-driven forecasting systems, essential medications can be delivered more efficiently and cost-effectively. These innovations can enhance drug availability and improve supply reliability, ensuring that patients in remote or economically disadvantaged areas receive timely and affordable access to necessary treatments. The integration of telepharmacy and blockchain technologies further ensures that the supply chain is secure, transparent,

and capable of responding to demand fluctuations. These innovations are essential to creating an equitable healthcare system where access to medications is not restricted by geography or socioeconomic status.

Both state and federal governments must adopt supportive policies to ensure the successful implementation of these supply chain innovations. Federal policies should focus on expanding access to telehealth and telepharmacy services and aligning regulations across states to create a more cohesive regulatory environment for mobile pharmacies and micro-fulfillment centers. Furthermore, the 340B Drug Pricing Program can be expanded to include more health systems in underserved areas, providing discounts on essential medications. State governments should incentivize partnerships between public and private entities, encouraging collaboration in building infrastructure to support last-mile delivery. Financial subsidies for low-income patients and coverage expansion in rural areas would also enhance affordability and reduce the financial burden of accessing essential medications. States should also work to remove medication reimbursement barriers, allowing innovative distribution models to thrive and ensure equitable access to health resources.

The role of technology and partnerships in shaping the future of healthcare supply chains is paramount. Technological advancements such as artificial intelligence, blockchain, and telehealth offer unparalleled opportunities to streamline distribution processes and enhance medication accessibility. For example, AI-driven demand forecasting allows for better inventory management and reduces the likelihood of drug shortages, while blockchain can provide real-time tracking and verification of medications, ensuring their safety and authenticity. When coupled with public-private partnerships, these technologies can drive collaboration between government entities, non-profits, and the private sector to build scalable and resilient supply chains. Such partnerships are critical for pooling resources, sharing expertise, and creating solutions tailored to the unique challenges faced by rural and low-income communities. Integrating technology and collaboration will be crucial to ensuring a robust, efficient, and equitable healthcare supply chain as the healthcare landscape evolves.

Future research should focus on developing scalable models for supply chain innovations that can be implemented across different geographic and economic contexts. Researchers should explore how mobile pharmacies and micro-fulfillment centers can be scaled from pilot projects to national systems, evaluating their feasibility, cost-effectiveness, and impact on medication access. Additionally, research should examine the long-term sustainability of these innovations, particularly in terms of financial viability, workforce requirements, and environmental impact. Studies should also focus on understanding the barriers and opportunities for integration across different technologies and ensuring interoperability between digital health tools and traditional healthcare systems. Lastly, the exploration of patient-centered models is essential to understanding how these supply chain innovations impact patient outcomes, medication adherence, and health equity. By addressing these research areas, policymakers and healthcare leaders can ensure that supply chain innovations are effective in the short term and sustainable and adaptable to future healthcare needs.

6. References

1. Adekola AD, Kassem RG, Mbata AO. Convergence of AI, blockchain and pharmacoeconomics in building adaptive pharmaceutical supply chains: A novel paradigm shift for equitable global drug access. [Journal Name Not Provided]. 2022.
2. Alli OI, Dada SA. Cross-cultural tobacco dependency treatment: A robust review of models for tailored interventions in diverse healthcare contexts. [Journal Name Not Provided]. 2023a.
3. Alli OI, Dada SA. Reducing maternal smoking through evidence-based interventions: Advances and emerging models in high-impact public health strategies. [Journal Name Not Provided]. 2023b.
4. Babarinde AO, Ayo-Farai O, Maduka CP, Okongwu CC, Sodamade O. Data analytics in public health, A USA perspective: A review. World Journal of Advanced Research and Reviews. 2023;20(3):211-24.
5. Baeten R, Spasova S, Vanhercke B, Coster S. Inequalities in access to healthcare. A study of national policies. European Social Policy Network (ESPN). Brussels: European Commission; 2018.
6. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, *et al*. Innovations in drug delivery systems: A review of the pharmacist's role in enhancing efficacy and patient compliance. World Journal of Advanced Research and Reviews. 2023;20(3):1268-82.
7. Bardhan R, Byrd T, Boyd J. Workforce management during the time of COVID-19—lessons learned and future measures. COVID. 2022;3(1):1-27.
8. Bors C, Christie A, Gervais D, Wright Clayton E. Improving access to medicines in low-income countries: a review of mechanisms. The Journal of World Intellectual Property. 2015;18(1-2):1-28.
9. Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A, Cheng X, *et al*. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. The Lancet Diabetes & Endocrinology. 2018;6(10):798-808.
10. Conti RM, Nikpay SS, Buntin MB. Revenues and profits from Medicare patients in hospitals participating in the 340B drug discount program, 2013-2016. JAMA Network Open. 2019;2(10):e1914141.
11. Ding B. Pharma Industry 4.0: Literature review and research opportunities in sustainable pharmaceutical supply chains. Process Safety and Environmental Protection. 2018;119:115-30.
12. Dutta P, Choi TM, Somani S, Butala R. Blockchain technology in supply chain operations: Applications, challenges and research opportunities. Transportation Research Part E: Logistics and Transportation Review. 2020;142:102067.
13. Edoh NL, Ukpabi UJ, Igoli JO. Effect of scopoletin and carotenoids on postharvest physiological deterioration (PPD) of transgenic high beta carotene cassava. Journal of Food Research. 2021;10(4):1-9.
14. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sensors International. 2021;2:100117.
15. Jönsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JMG, Wong O. Advanced therapy medicinal products and health technology assessment

principles and practices for value-based and sustainable healthcare. The European Journal of Health Economics. 2019;20:427-38.
16. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-71.
17. Knox RP, Kesselheim AS, Sarpatwari A. Risks to the 340B Drug Pricing Program related to manufacturer restrictions on drug availability. JAMA. 2022;327(17):1647-8.
18. Knox RP, Wang J, Feldman WB, Kesselheim AS, Sarpatwari A. Outcomes of the 340B Drug Pricing Program: A Scoping Review. JAMA Health Forum. 2023.
19. Kouhizadeh M, Saberi S, Sarkis J. Blockchain technology and the sustainable supply chain: Theoretically exploring adoption barriers. International Journal of Production Economics. 2021;231:107831.
20. Krasting N. Fraudulent medicines in the shadow of the pandemic. [Journal Name Not Provided]. 2021.
21. Lazar M, Davenport L. Barriers to health care access for low income families: a review of literature. Journal of Community Health Nursing. 2018;35(1):28-37.
22. Luiza VL, Chaves LA, Silva RM, Emmerick ICM, Chaves GC, de Araújo SCF, *et al*. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database of Systematic Reviews. 2015;(5).
23. Magnusson MM. Mapping open drug scenes (ODS). In: Crime and Fear in Public Places. Routledge; 2020:305-25.
24. Majebi NL, Drakeford OM, Adelodun MO, Chinyere E. Leveraging digital health tools to improve early detection and management of developmental disorders in children. [Journal Name Not Provided]. 2023.
25. Moosivand A, Ghatari AR, Rasekh HR. Supply chain challenges in pharmaceutical manufacturing companies: using qualitative system dynamics methodology. Iranian Journal of Pharmaceutical Research. 2019;18(2):1103.
26. Nuffer W, Trujillo T, Griend JV. Estimated potential financial impact of pharmacist-delivered disease management services across a network of pharmacies in rural Colorado. Journal of Managed Care & Specialty Pharmacy. 2019;25(9):984-8.
27. Olatunji G, Isarinade TD, Emmanuel K, Olatunji D, Aderinto N. Exploring the transformative role of drone technology in advancing healthcare delivery in Africa; a perspective. Annals of Medicine and Surgery. 2023;85(10):5279-84.
28. Saberi S, Kouhizadeh M, Sarkis J, Shen L. Blockchain technology and its relationships to sustainable supply chain management. International Journal of Production Research. 2019;57(7):2117-35.
29. Saeed G, Kohler JC, Cuomo RE, Mackey TK. A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain. Expert Opinion on Drug Safety. 2022;21(8):1061-88.
30. Satcher LA. Multiply-deserted areas: environmental racism and food, pharmacy, and greenspace access in the Urban South. Environmental Sociology. 2022;8(3):279-91.
31. Singh RK, Kumar R, Kumar P. Strategic issues in pharmaceutical supply chains: a review. International Journal of Pharmaceutical and Healthcare Marketing. 2016;10(3):234-57.
32. Talla RR. Integrating Blockchain and AI to Enhance Supply Chain Transparency in Energy Sectors. Asia Pacific Journal of Energy and Environment. 2022;9(2):109-18.
33. Touger R, Wood BR. A review of telehealth innovations for HIV pre-exposure prophylaxis (PrEP). Current HIV/AIDS Reports. 2019;16:113-9.
34. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation. 2016;133(21):2076-85.